Daruka Mahadevan - Concepedia

Author

Daruka Mahadevan

University of Arizona ORCID

Also Known As

D MAHADEVAN, D Mahadevan, D. MAHADEVAN, D. Mahadevan, D. S. A. Mahadevan, Daruka Mahadevan

107

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

University of Arizona University of Arizona Cancer Center Arizona Oncology The University of Texas MD Anderson Cancer Center West Cancer Center

About

Daruka Mahadevan is an author at University of Arizona specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	619
2	Cell Biology	5	5	169
3	Health Sciences	3	3	109
4	Natural Sciences	2	2	71
5	Biochemistry	2	2	71

Daruka Mahadevan

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Lenalidomide in Myelodysplastic Syndromes Alan F. List, S. Kurtin, Denise J. Roe, New England Journal of Medicine	2005	871
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Lawrence Fong, Andrew Hotson, John D. Powderly, Cancer Discovery	2019	321
Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas Jonathan W. Friedberg, Daruka Mahadevan, Erin Cebula, Journal of Clinical Oncology	2013	208
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies Daruka Mahadevan, E. Gabriela Chiorean, Wayne B. Harris, European Journal of Cancer Pro-drug Sf1126MedicinePharmacologyAdvanced Solid TumoursPharmacotherapy	2012	131
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures Daruka Mahadevan, Catherine Spier, Kimiko Della Croce, Molecular Cancer Therapeutics	2005	93
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma Daruka Mahadevan, Joseph M. Unger, Catherine Spier, Cancer	2012	86
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors Daruka Mahadevan, Ruth Plummer, Matthew Squires, Annals of Oncology Pharmacodynamic StudyOncologyMedicinePharmacotherapyRefractory Solid Tumors	2011	86
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200 Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Journal for ImmunoTherapy of Cancer	2019	82
A phase 1/2 trial of ublituximab, a novel anti‐ <scp>CD</scp> 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, British Journal of Haematology	2017	72
Ublituximab ( <scp>TG</scp> ‐1101), a novel glycoengineered anti‐ <scp>CD</scp> 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, British Journal of Haematology	2016	62

Page 1